Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients

Clinical trial NCT06900075 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06900075
Sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Type 2 Diabetes

Start date: 2025-07-30
Primary completion: 2026-01-30
Enrollment: 88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.